These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30701404)

  • 1. A Review of Telehealth Innovations for HIV Pre-Exposure Prophylaxis (PrEP).
    Touger R; Wood BR
    Curr HIV/AIDS Rep; 2019 Feb; 16(1):113-119. PubMed ID: 30701404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation Strategies to Increase PrEP Uptake in the South.
    Sullivan PS; Mena L; Elopre L; Siegler AJ
    Curr HIV/AIDS Rep; 2019 Aug; 16(4):259-269. PubMed ID: 31177363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings.
    Marcus JL; Volk JE; Pinder J; Liu AY; Bacon O; Hare CB; Cohen SE
    Curr HIV/AIDS Rep; 2016 Apr; 13(2):116-24. PubMed ID: 26898645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand.
    Azariah S; Saxton P; Franklin R; Forster R; Werder S; Jenkins R
    BMJ Open; 2019 Jun; 9(6):e026363. PubMed ID: 31248921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
    J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing HIV pre-exposure prophylaxis (PrEP): let's not get caught with our pants down.
    Saxton P; Giola M; Coughlan E; Rich J; Azariah S; Ludlam A; O'Toole C; Pohl M; Myers J
    N Z Med J; 2018 Aug; 131(1481):64-73. PubMed ID: 30161114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
    Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
    Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public Health Implications of Adapting HIV Pre-exposure Prophylaxis Programs for Virtual Service Delivery in the Context of the COVID-19 Pandemic: Systematic Review.
    Patel P; Kerzner M; Reed JB; Sullivan PS; El-Sadr WM
    JMIR Public Health Surveill; 2022 Jun; 8(6):e37479. PubMed ID: 35486813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Resistance During HIV Pre-Exposure Prophylaxis.
    Gibas KM; van den Berg P; Powell VE; Krakower DS
    Drugs; 2019 Apr; 79(6):609-619. PubMed ID: 30963509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 - 2023).
    Moyo E; Barham L; Mhango M; Musuka G; Dzinamarira T
    J Infect Public Health; 2022 Oct; 15(10):1147-1155. PubMed ID: 36162151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
    Landovitz RJ
    Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.